LOGIN  |  REGISTER
Chimerix

List of Biotechnology Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 463.13
29.98 6.92
2.08M
253.72M
US$ 117.510B
US$ 723.67
-18.33 -2.47
873,047
103.28M
US$ 74.740B
US$ 473.29
8.36 1.80
677,915
132.11M
US$ 62.530B
US$ 921.80
6.44 0.70
284,195
61.57M
US$ 56.760B
US$ 206.78
0.18 0.09
2.15M
213.27M
US$ 44.100B
US$ 96.73
0.62 0.65
6.21M
240.46M
US$ 23.260B
US$ 480.96
6.82 1.44
251,351
43.06M
US$ 20.710B
US$ 101.50
0.06 0.06
986,295
196.32M
US$ 19.930B
US$ 31.68
-0.03 -0.09
1.27M
615.99M
US$ 19.510B
US$ 184.71
0.00 0.00
0
97.68M
US$ 18.040B
US$ 39.60
0.07 0.18
3.03M
427.25M
US$ 16.920B
US$ 151.96
-0.52 -0.34
593,944
99.71M
US$ 15.150B
US$ 77.69
2.38 3.16
2.45M
193.32M
US$ 15.020B
US$ 20.70
0.60 2.99
7.93M
695.49M
US$ 14.400B
US$ 74.15
2.69 3.76
1.55M
192.71M
US$ 14.290B
US$ 131.87
0.00 0.00
0
106.24M
US$ 14.010B
US$ 18.37
1.12 6.49
3.84M
744.44M
US$ 13.680B
US$ 81.84
0.53 0.65
2.01M
161.97M
US$ 13.260B
US$ 579.89
6.74 1.18
235,544
22.71M
US$ 13.170B
US$ 200.50
-1.66 -0.82
388,070
61.10M
US$ 12.250B
US$ 44.01
0.57 1.31
2.26M
268.11M
US$ 11.800B
US$ 71.58
0.04 0.06
921,409
150.68M
US$ 10.790B
US$ 30.33
-2.11 -6.50
1,883
349.00M
US$ 10.590B
US$ 54.31
0.42 0.78
2.48M
192.11M
US$ 10.430B
US$ 167.10
0.39 0.23
640,130
60.77M
US$ 10.150B
US$ 63.82
0.87 1.38
1.58M
155.81M
US$ 9.940B
US$ 25.17
1.11 4.61
8.23M
390.73M
US$ 9.830B
US$ 106.91
0.00 0.00
0
84.98M
US$ 9.090B
US$ 65.08
7.12 12.29
3.90M
135.81M
US$ 8.840B
US$ 83.67
2.91 3.60
407,794
105.19M
US$ 8.800B
US$ 111.10
-3.73 -3.25
3.08M
77.90M
US$ 8.650B
US$ 129.46
0.00 0.00
0
64.58M
US$ 8.360B
US$ 64.66
1.15 1.81
1.28M
122.26M
US$ 7.910B
US$ 27.24
1.13 4.33
5.07M
282.15M
US$ 7.690B
US$ 64.66
-1.88 -2.83
1.67M
117.60M
US$ 7.600B
US$ 147.81
5.72 4.03
365,217
50.41M
US$ 7.450B
US$ 96.12
0.13 0.14
2.96M
75.85M
US$ 7.290B
US$ 106.90
1.94 1.85
249,212
67.27M
US$ 7.190B
US$ 104.63
3.24 3.20
389,383
66.74M
US$ 6.980B
US$ 220.98
1.09 0.50
642,065
31.45M
US$ 6.950B
US$ 217.46
2.40 1.12
174,189
29.00M
US$ 6.310B
US$ 47.70
3.00 6.71
1.44M
130.91M
US$ 6.240B
US$ 39.16
0.18 0.46
2.35M
153.51M
US$ 6.010B
US$ 86.07
1.42 1.68
581,824
62.52M
US$ 5.380B
US$ 55.99
4.41 8.55
1.71M
95.30M
US$ 5.340B
US$ 151.79
0.95 0.63
205,530
34.89M
US$ 5.300B
US$ 27.75
1.06 3.97
1.05M
184.69M
US$ 5.130B
US$ 31.61
0.98 3.20
1.63M
158.76M
US$ 5.020B
US$ 29.53
0.56 1.93
2.02M
165.12M
US$ 4.880B
US$ 32.89
0.70 2.17
920,008
145.68M
US$ 4.790B
US$ 65.99
1.72 2.68
392,459
71.95M
US$ 4.750B
US$ 19.72
0.47 2.44
2.67M
238.00M
US$ 4.690B
US$ 186.15
7.03 3.92
586,375
25.01M
US$ 4.660B
US$ 100.00
2.50 2.56
554,435
46.27M
US$ 4.630B
US$ 54.70
0.21 0.39
5.39M
82.32M
US$ 4.500B
US$ 46.98
1.97 4.38
909,677
94.89M
US$ 4.460B
US$ 43.51
2.43 5.92
2.17M
102.01M
US$ 4.440B
US$ 25.88
0.45 1.77
1.29M
169.18M
US$ 4.380B
US$ 29.07
0.56 1.96
4.25M
146.08M
US$ 4.250B
US$ 72.94
4.13 6.00
975,725
57.82M
US$ 4.220B
US$ 74.55
5.42 7.84
926,629
54.83M
US$ 4.090B
US$ 35.52
-2.81 -7.33
2.21M
113.39M
US$ 4.030B
US$ 22.71
0.69 3.13
958,052
175.28M
US$ 3.980B
US$ 193.03
-2.07 -1.06
139,086
19.68M
US$ 3.800B
US$ 47.75
1.59 3.44
625,682
79.05M
US$ 3.770B
US$ 29.96
0.53 1.80
1.87M
122.49M
US$ 3.670B
US$ 70.99
1.11 1.59
552,079
51.39M
US$ 3.650B
US$ 46.99
0.00 0.00
0
75.35M
US$ 3.540B
US$ 36.45
2.98 8.90
1.89M
96.48M
US$ 3.520B
US$ 92.38
2.66 2.96
225,679
37.75M
US$ 3.490B
US$ 81.88
2.44 3.07
297,070
42.45M
US$ 3.480B
US$ 42.61
1.24 3.00
709,615
80.67M
US$ 3.440B
US$ 44.29
1.41 3.29
707,885
77.28M
US$ 3.420B
US$ 25.63
0.20 0.79
1.59M
123.73M
US$ 3.170B
US$ 34.85
0.86 2.53
1.00M
89.47M
US$ 3.120B
US$ 39.20
0.05 0.13
2.87M
79.14M
US$ 3.100B
US$ 9.78
0.05 0.51
3.26M
308.53M
US$ 3.020B
US$ 34.34
0.65 1.93
1.26M
87.67M
US$ 3.010B
US$ 31.30
0.87 2.86
991,449
95.37M
US$ 2.990B
US$ 33.74
2.95 9.58
1.56M
87.00M
US$ 2.940B
US$ 20.09
0.10 0.50
2.49M
142.82M
US$ 2.870B
US$ 8.37
0.90 12.05
8.43M
341.83M
US$ 2.860B
US$ 23.10
0.48 2.12
869,181
122.91M
US$ 2.840B
US$ 19.00
1.16 6.50
1.30M
146.66M
US$ 2.790B
US$ 50.72
2.60 5.40
1.74M
53.71M
US$ 2.720B
US$ 26.74
3.37 14.42
2.35M
101.47M
US$ 2.710B
US$ 21.25
0.59 2.86
1.41M
126.53M
US$ 2.690B
US$ 41.26
4.01 10.77
3.88M
63.93M
US$ 2.640B
US$ 16.90
-1.79 -9.58
7.83M
152.67M
US$ 2.580B
US$ 32.20
3.80 13.38
1.51M
77.59M
US$ 2.500B
US$ 23.32
0.34 1.48
1.73M
105.87M
US$ 2.470B
US$ 11.46
0.21 1.87
2.59M
213.05M
US$ 2.440B
US$ 21.84
1.37 6.69
4.37M
104.79M
US$ 2.290B
US$ 14.89
0.00 0.00
0
148.49M
US$ 2.210B
US$ 19.76
0.24 1.23
628,551
110.59M
US$ 2.190B
US$ 2.21
0.12 5.74
25.08M
984.97M
US$ 2.180B
US$ 27.25
0.10 0.37
6.21M
80.16M
US$ 2.180B
US$ 16.93
0.36 2.17
151,167
128.29M
US$ 2.170B
US$ 37.00
0.99 2.75
614,673
57.60M
US$ 2.130B
US$ 31.77
0.42 1.34
39,461
65.90M
US$ 2.090B
US$ 59.98
0.00 0.00
0
34.44M
US$ 2.070B
US$ 14.91
-1.00 -6.29
4.08M
131.84M
US$ 1.970B
US$ 23.02
0.17 0.74
1.28M
85.15M
US$ 1.960B
US$ 26.22
1.12 4.46
420,927
74.84M
US$ 1.960B
US$ 29.95
5.83 24.17
11.09M
64.96M
US$ 1.950B
US$ 37.88
1.71 4.73
221,018
50.53M
US$ 1.910B
US$ 31.40
-0.72 -2.24
914,448
60.68M
US$ 1.910B
US$ 37.39
-0.26 -0.69
546,489
50.57M
US$ 1.890B
US$ 43.97
1.69 4.00
703,053
42.88M
US$ 1.890B
US$ 27.81
1.14 4.27
523,445
66.45M
US$ 1.850B
US$ 19.37
2.28 13.34
2.55M
91.71M
US$ 1.780B
US$ 30.96
1.15 3.86
644,115
57.12M
US$ 1.770B
US$ 13.70
0.35 2.62
2.28M
128.23M
US$ 1.760B
US$ 5.59
0.00 0.00
2.61M
307.07M
US$ 1.720B
US$ 16.83
0.48 2.94
1.06M
101.37M
US$ 1.710B
US$ 19.71
0.92 4.90
1.49M
86.91M
US$ 1.710B
US$ 7.85
0.69 9.64
11.57M
210.54M
US$ 1.650B
US$ 27.49
0.51 1.89
1.39M
58.31M
US$ 1.600B
US$ 25.48
0.16 0.63
2.43M
62.29M
US$ 1.590B
US$ 14.21
0.46 3.35
889,851
109.82M
US$ 1.560B
US$ 20.86
-0.12 -0.57
598,598
74.77M
US$ 1.560B
US$ 33.94
0.78 2.35
618,942
44.90M
US$ 1.520B
US$ 4.06
0.19 4.91
3.27M
363.19M
US$ 1.470B
US$ 26.97
1.96 7.84
417,377
54.04M
US$ 1.460B
US$ 4.64
0.04 0.87
1.14M
311.60M
US$ 1.450B
US$ 5.77
0.23 4.15
1.96M
242.97M
US$ 1.400B
US$ 7.83
0.34 4.54
1.47M
173.32M
US$ 1.360B
US$ 14.58
1.83 14.35
2.18M
92.40M
US$ 1.350B
US$ 29.16
22.80 358.49
70.97M
45.72M
US$ 1.330B
US$ 27.76
0.64 2.36
495,635
47.66M
US$ 1.320B
US$ 10.97
0.09 0.83
1.51M
117.42M
US$ 1.290B
US$ 9.57
-0.51 -5.06
2.08M
134.68M
US$ 1.290B
US$ 6.30
0.49 8.43
5.74M
203.47M
US$ 1.280B
US$ 10.34
0.45 4.55
369,900
121.56M
US$ 1.260B
US$ 3.56
0.08 2.30
2.23M
353.82M
US$ 1.260B
US$ 21.00
0.44 2.14
229,126
59.35M
US$ 1.250B
US$ 17.31
1.32 8.26
392,722
71.41M
US$ 1.240B
US$ 47.98
0.00 0.00
0
25.69M
US$ 1.230B
US$ 4.49
0.43 10.59
3.14M
273.92M
US$ 1.230B
US$ 43.76
2.86 6.99
534,465
27.69M
US$ 1.210B
US$ 82.96
0.71 0.86
98,107
14.54M
US$ 1.210B
US$ 22.90
0.90 4.09
551,932
53.05M
US$ 1.210B
US$ 9.12
0.29 3.28
3.07M
132.69M
US$ 1.210B
US$ 14.52
0.83 6.06
854,982
82.79M
US$ 1.200B
US$ 7.14
0.15 2.15
2.28M
167.18M
US$ 1.190B
US$ 4.47
0.50 12.59
12.32M
266.37M
US$ 1.190B
US$ 26.55
0.38 1.45
227,964
44.77M
US$ 1.190B
US$ 5.16
0.05 0.98
2.62M
225.17M
US$ 1.160B
US$ 11.94
-0.12 -1.00
1.18M
97.22M
US$ 1.160B
US$ 57.13
2.28 4.16
624,852
20.34M
US$ 1.160B
US$ 21.70
0.78 3.73
297,152
53.37M
US$ 1.160B
US$ 24.47
0.09 0.37
867,184
46.81M
US$ 1.150B
US$ 6.73
0.26 4.02
1.86M
165.92M
US$ 1.120B
US$ 6.84
0.24 3.64
4.09M
162.50M
US$ 1.110B
US$ 16.86
1.45 9.41
1.39M
65.12M
US$ 1.100B
US$ 18.99
0.20 1.06
41,274
57.81M
US$ 1.100B
US$ 40.00
0.00 0.00
0
27.02M
US$ 1.080B
US$ 15.81
-0.40 -2.47
7,506
68.51M
US$ 1.080B
US$ 10.98
0.33 3.10
1.29M
97.39M
US$ 1.070B
US$ 9.06
0.96 11.85
3.94M
115.83M
US$ 1.050B
US$ 3.49
0.03 0.87
6.68M
299.34M
US$ 1.040B
US$ 11.97
0.84 7.55
1.17M
87.02M
US$ 1.040B
US$ 14.67
-0.07 -0.47
1.27M
71.14M
US$ 1.040B
US$ 17.11
1.25 7.88
7.19M
60.15M
US$ 1.030B
US$ 21.03
0.54 2.64
20,445
48.22M
US$ 1.010B
US$ 15.55
0.00 0.00
0
64.53M
US$ 1.000B
US$ 18.16
1.01 5.89
224,747
54.78M
US$ 994.800M
US$ 11.13
0.00 0.00
0
89.31M
US$ 994.020M
US$ 18.89
0.46 2.50
317,811
50.67M
US$ 957.160M
US$ 13.35
0.83 6.63
3.11M
70.85M
US$ 945.850M
US$ 22.88
2.13 10.27
311,015
41.28M
US$ 944.490M
US$ 9.55
0.51 5.64
2.87M
98.85M
US$ 944.020M
US$ 3.29
0.40 13.84
9.13M
283.71M
US$ 933.410M
US$ 9.50
0.00 0.00
0
97.47M
US$ 925.960M
US$ 10.17
0.07 0.69
595,061
88.80M
US$ 903.100M
US$ 3.78
0.12 3.28
8.70M
237.07M
US$ 896.120M
US$ 14.38
0.33 2.35
194,526
62.03M
US$ 891.990M
US$ 32.09
-0.24 -0.74
202,883
27.71M
US$ 889.210M
US$ 9.47
0.58 6.52
1.42M
92.73M
US$ 878.150M
US$ 2.21
0.08 3.76
18.54M
396.97M
US$ 877.300M
US$ 28.00
0.69 2.53
1.91M
31.29M
US$ 876.120M
US$ 6.27
0.64 11.37
3.62M
139.13M
US$ 872.350M
US$ 47.21
2.80 6.30
320,935
18.15M
US$ 856.860M
US$ 8.31
-0.12 -1.42
4.90M
102.68M
US$ 853.270M
US$ 4.43
0.26 6.24
1.34M
192.32M
US$ 851.980M
US$ 12.67
1.01 8.66
1.46M
64.22M
US$ 813.670M
US$ 10.32
0.54 5.52
2.60M
78.79M
US$ 813.110M
US$ 1.27
0.04 3.25
20.74M
638.36M
US$ 810.720M
US$ 10.32
0.32 3.20
2.49M
78.44M
US$ 809.500M
US$ 12.49
0.00 0.00
0
63.96M
US$ 798.860M
US$ 3.42
0.43 14.38
6.27M
231.46M
US$ 791.590M
US$ 4.14
-0.04 -0.96
965,030
191.02M
US$ 790.820M
US$ 7.84
0.43 5.80
1.60M
97.21M
US$ 762.130M
US$ 10.06
0.28 2.86
2.38M
75.32M
US$ 757.720M
US$ 10.62
1.19 12.62
1.17M
70.90M
US$ 752.960M
US$ 6.17
0.24 4.05
1.92M
122.00M
US$ 752.740M
US$ 8.74
-0.03 -0.34
11,322
85.92M
US$ 750.940M
US$ 14.66
1.14 8.43
12.52M
50.55M
US$ 741.060M
US$ 8.70
7.97 1.00
161,739
85.14M
US$ 740.720M
US$ 7.64
0.06 0.79
53,860
96.33M
US$ 735.960M
US$ 17.16
0.00 0.00
0
41.89M
US$ 718.830M
US$ 4.00
0.19 4.99
3.28M
169.44M
US$ 677.760M
US$ 8.12
0.37 4.77
722,060
80.49M
US$ 653.580M
US$ 12.88
0.67 5.49
271,808
50.62M
US$ 651.990M
US$ 3.61
0.31 9.39
2.93M
180.51M
US$ 651.640M
US$ 4.28
0.22 5.42
1.38M
149.06M
US$ 637.980M
US$ 8.66
0.34 4.09
878,924
72.99M
US$ 632.090M
US$ 8.44
0.39 4.84
1.13M
74.68M
US$ 630.300M
US$ 10.50
0.30 2.94
808,579
59.08M
US$ 620.340M
US$ 10.70
0.57 5.63
609,803
57.14M
US$ 611.400M
US$ 11.17
0.82 7.92
714,544
53.83M
US$ 601.280M
US$ 7.83
0.00 0.00
0
76.38M
US$ 598.060M
US$ 3.41
0.00 0.00
0
171.00M
US$ 583.110M
US$ 8.16
0.00 0.00
0
69.23M
US$ 564.920M
US$ 7.84
-0.10 -1.26
7.76M
71.36M
US$ 559.460M
US$ 9.77
0.83 9.28
880,015
56.96M
US$ 556.500M
US$ 35.00
1.01 2.97
31,374
15.82M
US$ 553.700M
US$ 18.10
1.27 7.55
1.18M
30.47M
US$ 551.510M
US$ 8.68
0.00 0.00
0
62.78M
US$ 544.930M
US$ 5.14
0.38 7.98
2.04M
104.34M
US$ 536.310M
US$ 4.64
0.00 0.00
0
115.27M
US$ 534.850M
US$ 74.06
3.72 5.29
401,515
7.09M
US$ 525.090M
US$ 2.23
0.07 3.24
8.31M
233.12M
US$ 519.860M
US$ 77.19
1.25 1.65
119,437
6.68M
US$ 515.600M
US$ 3.51
0.07 2.03
669,898
145.02M
US$ 509.020M
US$ 1.40
0.06 4.48
2.87M
363.40M
US$ 508.760M
US$ 12.99
0.09 0.70
2.53M
38.87M
US$ 504.920M
US$ 3.29
0.26 8.58
3.91M
150.37M
US$ 494.720M
US$ 8.72
0.55 6.73
1.43M
56.30M
US$ 490.940M
US$ 9.06
0.11 1.23
641,886
54.12M
US$ 490.330M
C$ 6.16
0.21 3.53
386,175
78.34M
C$ 482.570M
US$ 22.31
1.50 7.21
35,015
21.22M
US$ 473.420M
US$ 3.81
-0.79 -17.17
11.53M
123.88M
US$ 471.980M
US$ 10.15
0.00 0.00
0
44.21M
US$ 448.730M
US$ 6.24
0.06 0.97
289,147
71.61M
US$ 446.850M
US$ 8.51
0.53 6.64
490,907
52.08M
US$ 443.200M
US$ 16.50
1.13 7.35
466,041
26.82M
US$ 442.530M
US$ 9.01
0.42 4.89
955,456
48.52M
US$ 437.170M
US$ 6.74
0.05 0.75
854,948
64.57M
US$ 435.200M
US$ 12.58
0.93 7.98
771,235
33.86M
US$ 425.960M
C$ 8.25
-0.02 -0.24
230,024
50.65M
C$ 417.860M
US$ 14.24
0.28 2.01
195,145
28.85M
US$ 410.820M
US$ 1.54
0.07 4.76
9.01M
265.37M
US$ 408.670M
US$ 4.57
0.90 24.52
13.40M
89.35M
US$ 408.330M
US$ 16.79
0.00 0.00
0
24.17M
US$ 405.810M
US$ 5.19
0.09 1.76
582,516
77.91M
US$ 404.350M
US$ 6.30
0.28 4.65
80,823
63.50M
US$ 400.050M
US$ 1.47
0.13 9.78
4.33M
266.14M
US$ 391.490M
US$ 8.60
0.00 0.00
0
45.44M
US$ 390.780M
US$ 1.68
0.07 4.35
1.15M
230.33M
US$ 386.950M
US$ 7.59
0.96 14.48
220,033
50.91M
US$ 386.410M
US$ 2.27
0.04 1.79
897,255
169.94M
US$ 385.760M
US$ 10.07
0.22 2.23
108,707
38.22M
US$ 384.880M
US$ 31.00
1.24 4.17
96,233
12.38M
US$ 383.780M
US$ 1.99
0.12 6.42
2.79M
192.09M
US$ 382.260M
US$ 3.65
0.00 0.00
0
104.39M
US$ 381.020M
US$ 1.21
0.05 4.31
21.35M
312.32M
US$ 377.910M
US$ 7.15
0.00 0.00
0
52.76M
US$ 377.230M
US$ 8.05
0.00 0.00
0
46.67M
US$ 375.690M
US$ 4.26
0.00 0.00
0
86.32M
US$ 367.720M
US$ 5.70
0.24 4.40
983,592
64.47M
US$ 367.480M
US$ 3.34
0.25 8.09
1.22M
108.22M
US$ 361.450M
US$ 13.39
0.59 4.61
691,326
26.97M
US$ 361.130M
US$ 5.25
0.15 2.94
892,033
68.75M
US$ 360.940M
US$ 7.14
0.27 3.93
1.27M
49.93M
US$ 356.500M
US$ 0.23
0.0007 0.30
1.89M
1.54B
US$ 355.740M
US$ 2.46
0.21 9.33
842,379
141.55M
US$ 348.210M
US$ 16.29
0.76 4.89
39,544
20.79M
US$ 338.670M
US$ 4.66
-0.05 -1.06
35,062
72.33M
US$ 337.060M
US$ 1.49
0.15 11.19
12.87M
224.73M
US$ 334.850M
US$ 3.88
0.01 0.26
37,438
85.26M
US$ 330.810M
US$ 9.22
0.73 8.60
211,341
35.86M
US$ 330.630M
US$ 7.18
0.62 9.45
287,310
43.80M
US$ 314.480M
US$ 1.96
0.21 12.00
19.92M
159.13M
US$ 311.890M
US$ 20.12
0.88 4.57
136,119
15.49M
US$ 311.660M
US$ 5.27
0.35 7.11
554,897
59.10M
US$ 311.460M
US$ 16.97
1.10 6.93
377,067
18.13M
US$ 307.670M
US$ 5.67
0.00 0.00
0
53.68M
US$ 304.370M
US$ 2.78
0.08 2.96
511,932
108.35M
US$ 301.210M
US$ 4.95
0.08 1.64
3.12M
60.16M
US$ 297.790M
US$ 4.06
0.02 0.50
2.90M
73.33M
US$ 297.720M
US$ 3.47
0.35 11.22
2.18M
85.59M
US$ 297.000M
US$ 2.90
0.13 4.69
744,622
100.60M
US$ 291.740M
US$ 4.60
0.69 17.65
1.26M
62.26M
US$ 286.400M
US$ 3.25
0.06 1.88
639,489
87.44M
US$ 284.180M
US$ 5.63
0.12 2.18
771,383
49.89M
US$ 280.630M
US$ 5.02
0.60 13.57
1.20M
54.90M
US$ 275.600M
US$ 4.86
0.09 1.89
260,257
56.46M
US$ 274.400M
US$ 1.88
0.17 9.94
303,209
143.96M
US$ 270.640M
US$ 5.00
0.00 0.00
0
53.23M
US$ 266.150M
US$ 1.92
0.08 4.35
23.94M
137.04M
US$ 263.120M
US$ 2.08
0.10 5.05
78,488
126.31M
US$ 262.720M
US$ 6.80
0.58 9.32
1.23M
38.59M
US$ 262.410M
US$ 5.19
0.32 6.57
386,389
50.39M
US$ 261.520M
US$ 4.88
0.33 7.25
1.54M
53.23M
US$ 259.760M
US$ 7.57
-0.04 -0.53
250,247
34.15M
US$ 258.520M
US$ 4.00
0.00 0.00
0
64.56M
US$ 258.240M
US$ 1.09
0.14 14.20
3.15M
236.29M
US$ 257.560M
US$ 11.12
0.63 6.01
121,494
23.10M
US$ 256.870M
US$ 4.73
0.18 3.96
1.39M
54.19M
US$ 256.320M
US$ 1.69
-0.14 -7.65
22.70M
149.00M
US$ 251.810M
US$ 4.44
0.15 3.50
153,455
56.55M
US$ 251.080M
US$ 1.70
-0.14 -7.61
268,172
147.19M
US$ 250.220M
US$ 4.85
0.00 0.00
0
50.00M
US$ 242.500M
US$ 1.29
0.03 2.38
5.01M
187.27M
US$ 241.580M
US$ 3.09
0.09 3.00
232,782
78.13M
US$ 241.420M
US$ 2.50
0.16 6.84
16.70M
96.27M
US$ 240.680M
US$ 4.23
0.46 12.20
866,731
55.60M
US$ 235.190M
US$ 1.27
0.10 8.55
8.72M
183.36M
US$ 232.870M
US$ 3.58
0.07 1.99
440,582
65.02M
US$ 232.770M
US$ 18.31
-0.78 -4.09
53,426
12.53M
US$ 229.420M
US$ 2.27
0.00 0.00
0
100.95M
US$ 229.160M
US$ 17.71
0.36 2.07
79,061
12.82M
US$ 227.040M
US$ 2.65
0.00 0.00
4.58M
85.17M
US$ 225.700M
US$ 2.30
0.19 9.00
3.18M
97.62M
US$ 224.530M
US$ 1.33
0.11 9.02
4.45M
166.51M
US$ 221.460M
US$ 1.55
0.16 11.44
8.73M
142.44M
US$ 220.640M
US$ 5.99
0.68 12.81
75,277
36.33M
US$ 217.620M
US$ 4.47
0.00 0.00
0
48.36M
US$ 216.170M
US$ 2.01
0.06 3.08
893,451
105.35M
US$ 211.750M
US$ 17.86
2.34 15.08
481,268
11.78M
US$ 210.390M
US$ 1.69
-0.10 -5.59
964,695
118.82M
US$ 200.810M
US$ 6.46
0.37 6.08
1.15M
31.00M
US$ 200.260M
US$ 3.42
0.04 1.18
1.70M
55.68M
US$ 190.430M
US$ 10.67
0.39 3.79
266,965
17.55M
US$ 187.260M
US$ 6.59
0.34 5.44
699,928
28.41M
US$ 187.220M
US$ 8.51
0.98 13.01
940,185
21.91M
US$ 186.450M
C$ 2.40
0.00 0.00
2,800
76.38M
C$ 183.310M
US$ 4.65
-0.08 -1.69
341,766
38.05M
US$ 176.930M
US$ 1.44
0.03 2.13
157,556
121.27M
US$ 174.630M
US$ 1.89
-0.06 -3.08
18,770
92.18M
US$ 174.220M
US$ 1.86
0.10 5.68
3.11M
93.47M
US$ 173.850M
US$ 6.65
-0.06 -0.89
736,620
26.00M
US$ 172.900M
US$ 7.43
0.10 1.36
50,341
23.24M
US$ 172.670M
US$ 0.50
0.06 13.36
48.57M
336.49M
US$ 167.910M
US$ 4.45
0.13 3.01
11,581
37.40M
US$ 166.430M
US$ 2.60
0.12 4.84
443,724
63.28M
US$ 164.530M
US$ 6.38
0.57 9.81
100,073
25.61M
US$ 163.390M
US$ 4.95
0.75 17.86
513,074
32.92M
US$ 162.950M
US$ 1.62
0.24 17.39
6.09M
97.54M
US$ 158.010M
US$ 17.44
0.74 4.43
104,672
9.05M
US$ 157.830M
US$ 1.77
0.16 9.94
3.72M
88.27M
US$ 156.240M
US$ 2.69
-0.76 -22.03
35.60M
56.97M
US$ 153.250M
US$ 1.69
0.04 2.42
2.98M
90.32M
US$ 152.640M
US$ 1.59
0.08 5.30
172,042
93.54M
US$ 148.730M
US$ 2.65
-0.01 -0.38
567,697
55.90M
US$ 148.140M
US$ 1.22
0.06 5.17
2.17M
120.87M
US$ 147.460M
US$ 3.73
0.13 3.61
2.86M
39.50M
US$ 147.340M
US$ 3.02
0.13 4.50
1.05M
48.31M
US$ 145.900M
US$ 21.99
0.00 0.00
0
6.60M
US$ 145.130M
US$ 4.17
0.00 0.00
438,694
34.01M
US$ 141.820M
US$ 2.09
0.05 2.45
3.82M
67.36M
US$ 140.780M
US$ 1.74
0.07 4.19
472,959
80.42M
US$ 139.930M
US$ 27.85
0.33 1.20
33,226
5.00M
US$ 139.250M
US$ 8.05
0.51 6.76
214,748
17.26M
US$ 138.940M
US$ 2.02
0.10 5.21
3.04M
68.70M
US$ 138.770M
US$ 9.47
0.04 0.42
148,433
14.42M
US$ 136.560M
US$ 15.75
0.21 1.35
97,734
8.57M
US$ 134.980M
US$ 1.06
0.04 3.92
43,655
126.01M
US$ 133.570M
C$ 1.60
0.07 4.58
84,472
83.41M
C$ 133.460M
US$ 6.17
0.31 5.29
992,106
21.49M
US$ 132.590M
US$ 6.15
0.17 2.84
73,111
20.92M
US$ 128.660M
US$ 2.28
0.08 3.64
1.63M
56.34M
US$ 128.460M
US$ 1.78
0.04 2.30
3.44M
71.03M
US$ 126.430M
US$ 5.81
0.09 1.57
310,931
21.74M
US$ 126.310M
US$ 1.14
0.00 0.00
11.82M
109.15M
US$ 124.430M
US$ 1.07
0.07 7.10
2.66M
115.35M
US$ 123.540M
US$ 4.65
0.24 5.44
1.34M
26.50M
US$ 123.220M
US$ 5.06
0.27 5.64
309,793
24.07M
US$ 121.790M
C$ 0.65
-0.03 -4.41
296,946
185.51M
C$ 120.580M
US$ 3.32
0.26 8.50
2.25M
36.24M
US$ 120.320M
US$ 1.59
0.11 7.43
990,497
75.03M
US$ 119.300M
US$ 1.93
0.18 10.29
360,059
60.57M
US$ 116.900M
US$ 8.41
0.41 5.12
75,014
13.85M
US$ 116.480M
US$ 1.56
0.00 0.00
4.84M
71.21M
US$ 111.090M
US$ 39.78
1.05 2.71
30,150
2.79M
US$ 110.990M
US$ 2.26
0.00 0.00
0
48.08M
US$ 108.660M
US$ 2.72
-0.03 -1.09
106,590
39.80M
US$ 108.260M
US$ 2.09
0.00 0.00
0
50.13M
US$ 104.770M
US$ 1.71
0.00 0.00
0
60.18M
US$ 102.910M
US$ 25.86
0.62 2.46
4,652
3.94M
US$ 101.890M
US$ 1.09
0.03 2.83
998,243
91.88M
US$ 100.150M
US$ 1.38
0.04 2.99
1.81M
72.25M
US$ 99.700M
US$ 1.89
0.00 0.00
167,596
51.76M
US$ 97.830M
US$ 2.06
0.07 3.52
46,242
47.13M
US$ 97.090M
US$ 90.00
0.80 0.90
96,835
1.07M
US$ 96.300M
US$ 0.91
0.03 2.95
2.75M
106.15M
US$ 96.170M
US$ 2.33
-0.05 -2.10
1,277
41.08M
US$ 95.720M
US$ 0.74
0.04 5.41
3.34M
129.17M
US$ 95.330M
US$ 1.54
0.05 3.36
2.83M
61.45M
US$ 94.630M
US$ 2.06
-0.16 -7.21
123,592
45.86M
US$ 94.470M
US$ 2.17
0.04 1.88
320,132
42.99M
US$ 93.290M
US$ 5.46
0.10 1.87
390,325
17.05M
US$ 93.090M
US$ 12.80
0.58 4.75
51,930
7.21M
US$ 92.290M
US$ 4.17
0.01 0.24
1.72M
22.08M
US$ 92.070M
US$ 1.93
0.00 0.00
0
46.15M
US$ 89.070M
US$ 1.40
-0.02 -1.41
9.45M
63.26M
US$ 88.560M
US$ 3.58
0.24 7.19
67,674
24.54M
US$ 87.850M
US$ 1.97
0.14 7.65
11.64M
44.42M
US$ 87.510M
US$ 0.36
-0.02 -4.96
113,915
240.06M
US$ 86.420M
US$ 2.45
0.08 3.38
811,588
35.04M
US$ 85.850M
US$ 0.55
-0.01 -2.34
9.27M
153.26M
US$ 83.830M
US$ 2.69
0.12 4.67
759,518
31.04M
US$ 83.500M
C$ 1.24
-0.04 -3.12
83,332
66.93M
C$ 82.990M
US$ 5.99
-0.07 -1.16
10,123
13.79M
US$ 82.600M
US$ 0.60
0.007 1.19
8.03M
137.43M
US$ 82.050M
US$ 7.93
-1.33 -14.36
4.95M
10.33M
US$ 81.920M
US$ 2.59
0.27 11.64
117,841
30.49M
US$ 78.970M
US$ 1.91
-0.06 -3.05
14,088
41.12M
US$ 78.540M
US$ 0.65
-0.002 -0.31
6.77M
120.28M
US$ 78.180M
US$ 11.49
0.71 6.59
59,729
6.78M
US$ 77.900M
US$ 2.68
0.00 0.00
0
28.91M
US$ 77.480M
US$ 8.28
0.06 0.73
141,238
9.25M
US$ 76.590M
US$ 0.77
0.07 9.30
4.56M
97.99M
US$ 75.550M
US$ 1.05
0.09 9.68
8.93M
70.70M
US$ 74.240M
US$ 1.51
0.04 2.72
105,694
49.05M
US$ 74.070M
US$ 3.00
0.00 0.00
0
24.68M
US$ 74.040M
US$ 2.28
0.08 3.64
499,135
31.56M
US$ 71.960M
US$ 1.32
0.12 10.00
1.13M
54.22M
US$ 71.570M
US$ 7.48
0.75 11.14
170,314
9.49M
US$ 70.990M
US$ 1.02
0.03 2.61
9.33M
67.75M
US$ 69.100M
US$ 1.38
0.03 2.22
491,670
50.02M
US$ 69.030M
US$ 1.29
0.06 4.88
2.48M
53.21M
US$ 68.640M
US$ 2.41
0.14 6.17
928,089
28.10M
US$ 67.720M
US$ 4.69
0.09 1.96
38,780
14.41M
US$ 67.580M
US$ 5.69
0.00 0.00
0
11.82M
US$ 67.260M
US$ 0.58
0.03 4.95
8.93M
115.06M
US$ 67.080M
US$ 1.77
0.22 14.19
2.39M
37.55M
US$ 66.460M
US$ 3.96
0.18 4.76
1.01M
16.63M
US$ 65.850M
US$ 3.25
-0.06 -1.81
39,632
20.16M
US$ 65.520M
US$ 1.72
0.14 8.86
993,845
37.77M
US$ 64.960M
C$ 0.70
0.00 0.00
11,000
90.68M
C$ 63.480M
US$ 3.48
0.14 4.31
21,670
18.13M
US$ 63.160M
US$ 2.57
0.02 0.78
35,223
24.30M
US$ 62.450M
US$ 1.75
0.09 5.42
207,762
35.21M
US$ 61.620M
US$ 2.20
0.10 4.76
451,169
26.29M
US$ 57.840M
C$ 0.51
0.02 4.08
34,000
113.01M
C$ 57.640M
US$ 9.19
0.18 2.00
226,913
6.24M
US$ 57.350M
US$ 2.02
0.00 0.00
175,066
28.32M
US$ 57.210M
US$ 6.04
0.76 14.39
1.92M
9.42M
US$ 56.900M
US$ 4.56
-0.06 -1.30
28,374
12.02M
US$ 54.810M
US$ 0.88
0.00 0.00
0
60.97M
US$ 53.650M
US$ 1.02
0.07 7.12
4.85M
52.47M
US$ 53.520M
C$ 1.95
0.04 2.09
14,262
27.42M
C$ 53.470M
US$ 0.87
0.01 1.48
889,232
60.89M
US$ 53.100M
US$ 9.87
0.66 7.17
43,477
5.35M
US$ 52.800M
US$ 10.93
0.21 1.96
6,170
4.69M
US$ 51.260M
C$ 0.92
0.10 12.20
103,005
54.73M
C$ 50.350M
US$ 9.81
0.00 0.00
0
5.02M
US$ 49.250M
C$ 0.07
-0.01 -12.50
39,000
701.73M
C$ 49.120M
US$ 4.97
0.00 0.00
0
9.79M
US$ 48.660M
US$ 0.83
0.05 5.98
4.33M
58.79M
US$ 48.560M
C$ 0.15
0.005 3.57
17,908
328.69M
C$ 47.660M
US$ 5.96
-0.97 -14.00
167,281
7.99M
US$ 47.620M
US$ 5.25
0.25 5.00
7,801
9.05M
US$ 47.510M
US$ 1.14
0.00 0.00
0
41.10M
US$ 46.850M
US$ 1.76
0.19 12.10
1.86M
26.59M
US$ 46.800M
US$ 0.85
0.08 10.87
761,631
54.72M
US$ 46.570M
US$ 1.27
0.00 0.00
0
36.59M
US$ 46.470M
US$ 0.64
0.0085 1.34
3.62M
71.95M
US$ 46.120M
US$ 1.34
0.05 3.88
229,311
34.38M
US$ 46.070M
US$ 2.73
0.00 0.00
0
16.84M
US$ 45.970M
US$ 1.74
0.00 0.00
0
26.31M
US$ 45.780M
US$ 6.24
0.09 1.46
20,725
7.32M
US$ 45.680M
US$ 1.62
0.04 2.53
4.55M
27.98M
US$ 45.330M
US$ 1.45
0.07 5.07
151,008
31.20M
US$ 45.240M
US$ 3.17
0.03 0.96
38,217
14.13M
US$ 44.790M
US$ 0.51
-0.02 -3.65
5.39M
87.31M
US$ 44.700M
US$ 0.92
0.06 6.74
3.79M
48.54M
US$ 44.560M
US$ 1.89
-0.04 -2.07
62,296
23.43M
US$ 44.280M
US$ 5.10
-0.02 -0.39
44,367
8.34M
US$ 42.530M
US$ 1.36
-0.09 -6.21
9,768
31.24M
US$ 42.490M
US$ 1.91
0.04 2.14
1.20M
21.87M
US$ 41.770M
US$ 1.12
-0.06 -5.08
429,182
37.03M
US$ 41.470M
US$ 12.04
-0.52 -4.14
254,466
3.39M
US$ 40.800M
US$ 0.09
-0.008 -8.16
31,081
442.60M
US$ 39.830M
US$ 3.54
0.07 2.02
503,862
11.18M
US$ 39.580M
US$ 1.22
0.11 9.91
1.10M
32.06M
US$ 39.110M
US$ 3.10
0.00 0.00
0
12.59M
US$ 39.030M
US$ 10.18
0.00 0.00
0
3.81M
US$ 38.790M
C$ 0.14
-0.005 -3.57
6,501
287.34M
C$ 38.790M
US$ 9.99
0.29 2.99
121,855
3.82M
US$ 38.160M
US$ 4.34
0.00 0.00
0
8.65M
US$ 37.540M
US$ 3.48
-0.33 -8.66
53,061
10.66M
US$ 37.100M
US$ 0.70
-0.0027 -0.38
1.24M
52.50M
US$ 36.960M
US$ 1.23
0.09 7.89
269,672
29.70M
US$ 36.530M
C$ 0.22
0.00 0.00
0
165.94M
C$ 36.510M
US$ 1.38
-0.10 -6.76
2.90M
26.29M
US$ 36.280M
US$ 5.56
0.02 0.36
35,896
6.37M
US$ 35.420M
US$ 2.04
0.01 0.49
1.06M
17.34M
US$ 35.370M
US$ 5.23
0.12 2.35
78,727
6.74M
US$ 35.250M
US$ 22.14
2.80 14.48
117,137
1.59M
US$ 35.200M
US$ 1.33
0.00 0.00
0
26.20M
US$ 34.850M
US$ 0.94
0.04 4.05
383,497
36.19M
US$ 34.090M
US$ 2.62
0.00 0.00
368,945
12.86M
US$ 33.690M
C$ 0.24
0.00 0.00
9,959
140.26M
C$ 33.660M
US$ 0.90
0.06 6.94
352,199
36.65M
US$ 33.130M
US$ 1.42
0.00 0.00
0
23.18M
US$ 32.920M
US$ 8.12
0.04 0.50
15,297
4.05M
US$ 32.890M
C$ 0.43
0.00 0.00
0
74.76M
C$ 32.150M
US$ 3.42
0.06 1.79
15,046
9.25M
US$ 31.640M
C$ 0.60
-0.05 -7.69
25,400
51.84M
C$ 31.100M
US$ 0.21
-0.0019 -0.89
16.46M
144.30M
US$ 30.450M
US$ 0.55
0.00 0.00
0
55.22M
US$ 30.370M
US$ 0.74
0.02 3.37
18,034
40.83M
US$ 30.210M
US$ 0.33
0.00 0.00
0
90.38M
US$ 29.740M
US$ 13.84
-0.06 -0.43
88,242
2.14M
US$ 29.620M
US$ 1.65
-0.22 -11.76
2,200
17.17M
US$ 28.330M
US$ 0.30
-0.004 -1.31
479,031
92.87M
US$ 28.050M
US$ 0.66
0.01 1.57
80,084
42.24M
US$ 27.880M
US$ 8.59
0.56 6.97
16,036
3.18M
US$ 27.320M
US$ 3.95
0.06 1.54
93,510
6.76M
US$ 26.700M
US$ 2.07
-0.07 -3.36
12,623
12.78M
US$ 26.430M
US$ 0.63
0.00 0.00
0
41.21M
US$ 25.840M
US$ 1.11
0.05 4.72
73,915
22.23M
US$ 24.680M
US$ 5.32
0.00 0.00
0
4.57M
US$ 24.310M
US$ 1.08
-0.01 -0.92
152,578
22.39M
US$ 24.180M
US$ 0.40
0.05 12.86
3.69M
60.06M
US$ 24.140M
US$ 12.64
2.64 26.40
167,448
1.88M
US$ 23.760M
US$ 1.75
0.03 1.45
122,375
13.48M
US$ 23.520M
US$ 1.04
-0.03 -2.80
8.04M
22.49M
US$ 23.390M
US$ 3.33
0.08 2.46
95,246
6.99M
US$ 23.280M
US$ 1.38
0.11 8.66
513,851
16.85M
US$ 23.250M
US$ 4.19
-0.18 -4.12
313,321
5.38M
US$ 22.540M
US$ 1.21
-0.05 -3.97
783,984
18.47M
US$ 22.350M
US$ 13.33
3.27 32.50
226,922
1.67M
US$ 22.260M
US$ 2.13
0.08 3.90
30,842
10.19M
US$ 21.700M
US$ 0.37
0.00 0.00
0
59.25M
US$ 21.630M
C$ 0.16
0.00 0.00
0
132.87M
C$ 21.260M
US$ 1.75
0.01 0.57
3,379
11.73M
US$ 20.530M
US$ 2.36
0.00 0.00
0
8.62M
US$ 20.340M
US$ 0.42
0.003 0.72
855,436
48.05M
US$ 20.040M
US$ 1.11
0.02 1.83
248,703
18.00M
US$ 19.980M
US$ 1.07
0.01 0.94
51,781
18.06M
US$ 19.320M
US$ 1.20
0.06 5.26
458,181
15.51M
US$ 18.610M
US$ 36.67
2.17 6.29
140,888
505,798
US$ 18.550M
US$ 8.86
0.59 7.13
28,320
2.08M
US$ 18.430M
US$ 13.60
0.00 0.00
0
1.32M
US$ 17.950M
US$ 3.09
-0.16 -4.92
14,480
5.55M
US$ 17.150M
US$ 1.93
0.03 1.32
22,197
8.82M
US$ 16.980M
US$ 2.11
-0.05 -2.31
387,861
7.99M
US$ 16.860M
US$ 1.27
0.08 6.72
146,831
12.94M
US$ 16.430M
US$ 1.25
0.05 4.17
104,422
12.93M
US$ 16.160M
US$ 3.27
0.24 7.92
813,418
4.93M
US$ 16.120M
US$ 4.38
-0.05 -1.13
5,656
3.65M
US$ 15.990M
US$ 1.09
-0.11 -9.17
678,441
14.52M
US$ 15.830M
US$ 7.36
-0.08 -1.08
24,098
2.15M
US$ 15.820M
US$ 3.69
0.07 1.93
87,911
4.24M
US$ 15.650M
US$ 1.55
-0.03 -1.90
182,984
10.09M
US$ 15.640M
US$ 0.26
-0.0082 -3.12
5.24M
61.29M
US$ 15.630M
C$ 0.06
0.00 0.00
0
258.84M
C$ 15.530M
C$ 0.09
0.00 0.00
156,148
181.05M
C$ 15.390M
US$ 2.49
-0.04 -1.58
148,290
6.16M
US$ 15.340M
C$ 0.20
0.00 0.00
0
76.57M
C$ 15.310M
US$ 1.30
-0.12 -8.45
23,645
11.70M
US$ 15.210M
US$ 3.85
-0.35 -8.33
23,298
3.94M
US$ 15.170M
US$ 0.27
0.005 1.91
860,463
56.64M
US$ 15.120M
US$ 1.42
0.05 3.65
88,139
10.61M
US$ 15.070M
US$ 17.83
-1.35 -7.04
215,155
838,977
US$ 14.950M
US$ 0.94
0.0082 0.88
21,904
15.49M
US$ 14.560M
US$ 0.05
0.00 0.00
0
265.05M
US$ 14.550M
US$ 1.04
0.03 2.97
39,353
13.78M
US$ 14.330M
C$ 0.03
0.00 0.00
0
570.65M
C$ 14.270M
US$ 3.22
0.02 0.62
14,693
4.35M
US$ 14.010M
US$ 1.29
0.06 4.88
1.10M
10.76M
US$ 13.880M
US$ 0.65
0.007 1.09
832,902
19.85M
US$ 12.920M
US$ 1.72
-0.007 -0.40
5,996
7.34M
US$ 12.650M
US$ 0.38
0.02 4.84
2.06M
33.29M
US$ 12.480M
US$ 0.34
-0.0054 -1.56
2.27M
35.74M
US$ 12.150M
US$ 3.96
0.05 1.15
11,897
3.07M
US$ 12.140M
US$ 1.59
0.12 8.16
43,061
7.54M
US$ 11.990M
US$ 0.22
0.00 0.00
0
55.66M
US$ 11.990M
US$ 0.40
0.03 7.85
737,884
29.71M
US$ 11.910M
US$ 2.42
0.36 17.48
98,597
4.81M
US$ 11.640M
US$ 8.70
0.50 6.10
20,027
1.26M
US$ 10.960M
US$ 0.85
-0.002 -0.23
77,166
12.85M
US$ 10.950M
C$ 0.12
0.00 0.00
64,140
91.02M
C$ 10.920M
US$ 1.50
0.07 4.90
98,229
7.17M
US$ 10.760M
US$ 5.34
4.78 855.28
43,323
1.92M
US$ 10.250M
C$ 0.07
0.00 0.00
0
151.90M
C$ 9.870M
C$ 0.09
0.00 0.00
133,919
108.62M
C$ 9.780M
US$ 1.37
-0.37 -21.26
100.20M
6.95M
US$ 9.520M
US$ 0.82
0.02 3.15
53,271
11.64M
US$ 9.490M
US$ 1.06
0.02 1.92
14,331
8.88M
US$ 9.410M
US$ 0.20
0.00 0.00
0
47.31M
US$ 9.320M
US$ 1.15
-0.05 -4.17
96,331
7.85M
US$ 9.030M
US$ 1.30
0.00 0.00
0
6.83M
US$ 8.880M
US$ 1.37
0.07 5.38
63,339
6.35M
US$ 8.700M
US$ 2.72
0.00 0.00
0
3.18M
US$ 8.650M
US$ 1.16
-0.03 -2.52
3.40M
7.44M
US$ 8.630M
US$ 2.75
0.20 7.84
104,786
3.13M
US$ 8.610M
US$ 8.56
0.00 0.00
0
973,291
US$ 8.330M
US$ 0.36
0.00 0.00
0
23.14M
US$ 8.210M
US$ 1.75
-0.03 -1.69
21,481
4.63M
US$ 8.100M
US$ 4.24
0.26 6.53
60,178
1.91M
US$ 8.100M
US$ 3.56
0.28 8.54
95,046
2.23M
US$ 7.940M
US$ 0.14
0.00 0.00
0
55.37M
US$ 7.900M
US$ 2.06
0.01 0.49
55,181
3.80M
US$ 7.830M
US$ 2.10
0.21 11.11
89,353
3.68M
US$ 7.730M
US$ 8.41
-0.54 -6.03
10,728
916,968
US$ 7.710M
US$ 1.19
-0.02 -1.65
78,458
6.45M
US$ 7.680M
C$ 0.15
-0.005 -3.33
2,500
52.95M
C$ 7.680M
US$ 0.93
-0.18 -15.91
5.20M
8.21M
US$ 7.590M
US$ 0.32
0.0021 0.67
300,887
23.99M
US$ 7.560M
US$ 4.19
0.18 4.49
36,879
1.77M
US$ 7.420M
US$ 7.10
-0.23 -3.17
8.08M
1.04M
US$ 7.380M
US$ 0.79
-0.03 -3.25
587,553
9.03M
US$ 7.090M
US$ 0.02
-0.003 -12.50
70,100
332.96M
US$ 6.990M
US$ 0.21
0.0011 0.53
3.15M
33.74M
US$ 6.980M
US$ 3.28
-0.03 -0.91
74,695
2.09M
US$ 6.860M
US$ 0.60
-0.02 -3.23
817
11.03M
US$ 6.620M
US$ 1.03
0.01 0.98
106,666
6.31M
US$ 6.500M
US$ 0.61
-0.15 -19.57
6.98M
10.64M
US$ 6.470M
US$ 0.07
-0.0074 -9.56
2,000
88.99M
US$ 6.230M
US$ 4.61
0.00 0.00
0
1.33M
US$ 6.120M
US$ 0.46
0.0004 0.09
85,993
13.32M
US$ 6.070M
US$ 2.84
0.00 0.00
0
2.12M
US$ 6.020M
US$ 0.20
0.00 0.00
0
30.12M
US$ 5.930M
US$ 1.07
0.11 11.59
232,496
5.48M
US$ 5.860M
US$ 1.53
0.00 0.00
56,243
3.81M
US$ 5.830M
C$ 2.85
0.06 2.15
7,297
2.04M
C$ 5.810M
US$ 0.34
-0.03 -8.53
690,802
17.07M
US$ 5.800M
US$ 2.21
0.001 0.05
35,239
2.58M
US$ 5.700M
US$ 0.95
0.0065 0.69
127,527
5.92M
US$ 5.640M
US$ 0.94
0.00 0.00
0
5.97M
US$ 5.580M
US$ 2.42
-0.03 -1.22
88,161
2.29M
US$ 5.540M
US$ 0.79
0.04 5.07
1.45M
6.80M
US$ 5.340M
US$ 2.88
-0.02 -0.69
21,269
1.83M
US$ 5.270M
US$ 0.78
-0.03 -3.51
29,161
6.41M
US$ 5.000M
C$ 0.03
0.00 0.00
0
166.23M
C$ 4.990M
US$ 0.84
-0.01 -1.57
325,583
5.86M
US$ 4.930M
US$ 1.28
-0.05 -3.76
21,294
3.84M
US$ 4.920M
US$ 0.91
0.00 0.00
0
5.17M
US$ 4.700M
US$ 1.58
0.01 0.64
44,085
2.97M
US$ 4.690M
US$ 2.99
0.42 16.34
105,607
1.56M
US$ 4.660M
US$ 2.83
0.09 3.28
626,490
1.63M
US$ 4.610M
US$ 0.34
0.00 0.00
0
13.54M
US$ 4.560M
US$ 1.05
0.00 0.00
0
4.25M
US$ 4.460M
US$ 2.06
0.07 3.52
29,328
2.15M
US$ 4.430M
US$ 0.63
-0.007 -1.09
8,990
6.96M
US$ 4.410M
C$ 0.01
0.00 0.00
227,499
432.32M
C$ 4.320M
US$ 1.02
0.03 2.99
18,405
4.23M
US$ 4.310M
US$ 0.50
0.00 0.00
0
8.21M
US$ 4.110M
US$ 0.37
0.02 6.06
169,978
10.74M
US$ 3.980M
US$ 1.17
-0.02 -1.68
24,870
3.33M
US$ 3.900M
US$ 0.53
0.00 0.00
0
7.24M
US$ 3.840M
US$ 6.66
0.15 2.30
10,118
574,580
US$ 3.830M
US$ 1.02
-0.14 -12.07
301,615
3.74M
US$ 3.810M
US$ 0.03
0.00 0.00
0
118.11M
US$ 3.800M
US$ 2.16
0.16 8.00
10,568
1.75M
US$ 3.780M
US$ 1.34
0.02 1.52
75,491
2.80M
US$ 3.750M
US$ 0.11
-0.02 -14.35
111.22M
33.18M
US$ 3.680M
US$ 1.15
0.12 11.65
58,439
3.19M
US$ 3.670M
US$ 1.80
0.00 0.00
58.37M
2.02M
US$ 3.640M
US$ 1.88
-0.01 -0.53
34,648
1.93M
US$ 3.630M
US$ 0.86
0.01 1.28
33,019
4.17M
US$ 3.600M
US$ 5.90
0.08 1.37
20,502
596,978
US$ 3.520M
US$ 2.00
0.00 0.00
0
1.61M
US$ 3.220M
C$ 0.01
0.00 0.00
0
312.86M
C$ 3.130M
US$ 3.01
0.02 0.67
14,468
1.03M
US$ 3.100M
US$ 4.91
0.05 1.03
51,530
619,523
US$ 3.040M
C$ 0.03
0.00 0.00
0
121.27M
C$ 3.030M
US$ 0.91
0.14 18.94
399
3.18M
US$ 2.890M
US$ 0.66
0.27 67.73
734.53M
4.34M
US$ 2.860M
C$ 0.08
0.00 0.00
0
34.26M
C$ 2.740M
C$ 0.12
-0.01 -7.69
38,900
21.15M
C$ 2.540M
US$ 0.56
0.00 0.00
0
4.52M
US$ 2.530M
US$ 0.02
0.00 0.00
0
124.38M
US$ 2.490M
US$ 0.06
0.0061 11.98
260,019
41.85M
US$ 2.390M
US$ 0.25
0.00 0.00
0
9.66M
US$ 2.390M
C$ 0.03
0.00 0.00
0
75.74M
C$ 2.270M
US$ 0.39
0.00 0.00
0
5.23M
US$ 2.040M
US$ 0.02
0.00 0.00
0
75.46M
US$ 1.810M
US$ 0.10
0.00 0.00
0
17.21M
US$ 1.800M
US$ 0.05
0.006 13.04
98,787
33.71M
US$ 1.750M
US$ 2.78
0.30 12.10
524,179
559,444
US$ 1.560M
US$ 0.31
0.03 11.79
6,142
4.62M
US$ 1.430M
C$ 0.005
0.00 0.00
0
283.28M
C$ 1.420M
US$ 0.09
0.00 0.00
0
16.39M
US$ 1.390M
C$ 0.09
0.00 0.00
0
13.86M
C$ 1.250M
US$ 0.14
0.0094 7.04
2,320
8.10M
US$ 1.160M
US$ 0.30
0.00 0.00
0
3.78M
US$ 1.130M
US$ 1.72
-0.11 -5.77
377,094
578,625
US$ 992K
US$ 0.20
0.00 0.00
0
4.44M
US$ 894K
US$ 0.06
-0.02 -22.50
5
11.62M
US$ 720K
US$ 0.11
0.00 0.00
0
6.58M
US$ 705K
US$ 0.02
0.00 0.00
0
29.49M
US$ 678K
US$ 0.001
-0.0006 -37.50
5.36M
635.87M
US$ 636K
US$ 0.07
0.00 0.00
0
8.31M
US$ 607K
US$ 0.25
0.00 0.00
0
1.63M
US$ 413K
US$ 0.21
0.00 0.00
0
1.55M
US$ 326K
US$ 0.008
0.00 0.00
0
39.74M
US$ 318K
US$ 0.07
0.00 0.00
0
4.44M
US$ 289K
US$ 0.004
0.00 0.00
0
61.76M
US$ 247K
US$ 0.001
0.00 0.00
0
232.37M
US$ 232K
US$ 0.37
0.00 0.00
0
581,000
US$ 215K
US$ 0.16
0.00 0.00
0
1.33M
US$ 206K
US$ 0.02
0.00 0.00
0
4.85M
US$ 97K
US$ 0.005
0.00 0.00
0
5.23M
US$ 26K
US$ 0.02
0.00 0.00
0
1.24M
US$ 26K
US$ 0.01
0.00 0.00
0
863,788
US$ 10K
US$ 0.07
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
4.87M
US$ -
US$ 1.06
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 3.01
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 32.95
0.00 0.00
0
-
US$ -
US$ 1.20
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
1.39M
US$ -
US$ 0.00
0.00 0.00
0
125.63M
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 0.02
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
5.12B
US$ -
US$ 0.02
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
261.79M
US$ -
US$ 1.98
0.03 1.54
102,611
-
US$ -
C$ 3.35
0.00 0.00
100
-
C$ -
US$ 1.78
0.20 12.66
556,952
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest Biotechnology Stock News


NovaBridge Biosciences Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistance The Phase 1 ragistomig study achieved its objective, as the new Q6W extended dosing interval produced strong anti-tumor efficacy in PD-L1-non-responders, with an improved safety profile The interim results, including immunological data on CD8+ cell proliferation and... Read more


Apellis Pharmaceuticals: The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Consistent results across adolescent and adult patients with C3G and primary IC-MPGN, including patients with C3G recurring after transplant EMPAVELI is the first FDA-approved treatment for C3G and primary IC-MPGN patients 12 and older WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE)... Read more


Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025

Event to Review R&D Progress and Outline Exelixis’ Strategy for Building Next-generation Oncology Franchises  ALAMEDA, Calif. / Dec 03, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast its virtual event, Exelixis 2025 R&D Day: Building Next-generation Oncology Franchises, on Wednesday, December 10, 2025, from 1:00 p.m. to 3:30 p.m. EST. During the event, featured speakers will review the progress of Exelixis’ R&D... Read more


TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated data from the ALLOHA™ Phase 1 trial being presented at the 67th American Society of Hematology (ASH) Annual Meeting... Read more


ORIC Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced two late-breaking oral presentations highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025... Read more


Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

NEW YORK, Dec. 3, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic pipeline. The Company detailed meaningful progress across HT-001, HT-KIT, HT-ALZ, and its newly launched GDNF-based metabolic program, while continuing to strengthen its global intellectual-property portfolio and expand strategic research partnerships. Pipeline Highlights HT-001... Read more


Virax Biolabs Announces $5 Million Private Placement

LONDON, Dec. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today that it has entered into definitive agreements for the purchase and sale of 12,500,000 ordinary shares (or ordinary share equivalents) and preferred investment options to purchase up to an aggregate of 12,500,000 ordinary shares at a purchase... Read more


Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Superior Mucoadhesion may potentially Translate into More Reliable Opioid Overdose Reversal in Real-World Emergencies Ra’anana, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced compelling new preclinical data showing its proprietary naloxone hydrogel adheres to nasal tissue longer than an approved and marketed... Read more


Oncotelic Therapeutics and Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing

AGOURA HILLS, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano today announced new pharmacokinetic (PK) and tissue-distribution results demonstrating that Sapu003, the company’s intravenous (IV) Deciparticle™ formulation of everolimus, substantially reduces gastrointestinal (GI) drug accumulation, addressing one of the most significant and well-recognized limitations of oral everolimus (Afinitor®).... Read more


Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple...

Biomarker-activated cancer drug-candidate LP-184 demonstrates encouraging efficacy signals in DNA damage repair deficient tumors with an acceptable safety and tolerability profile – meeting all primary endpoints. LP-184 demonstrated clinical benefit in multiple highly aggressive cancers with a 54% disease control rate at or above therapeutic dose levels. Multiple Phase 1b/2 clinical trials are now being planned across cancer indications and supported by 3 FDA Orphan... Read more


Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood

TORONTO, ON / ACCESS Newswire / December 3, 2025 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND) (OTC PINK:BMNDF) (FRA:3XI), a clinical-stage biopharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs, today announced a major strategic advancement in the development of BMND08, transitioning the program into FDA-directed activities using the Company's newly engineered nano-formulation... Read more


Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting

CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that data from its novel cell therapy platform will be shared in an oral presentation at the 67th ASH Annual Meeting, being held December 6-9, 2025 in Orlando, FL. “Being selected to give an oral presentation at ASH is a tremendous honor and a major m... Read more


Xenon Pharmaceuticals Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

VANCOUVER, British Columbia and BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its data presentations at the American Epilepsy Society Annual Meeting (AES 2025), including new long-term data... Read more


PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

NDA to be Submitted on a Rolling Basis, Beginning Early 2026 PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a formal pre-New Drug Application (“NDA”) meeting minutes from the U.S. Food and Drug Administration (“FDA”) supporting the NDA submission of D-PLEX100, the Company’s lead... Read more


Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced...

Findings further validate FABP5 inhibition and strengthen the therapeutic potential of Artelo’s FABP5 platform for mood and stress-related disorders SOLANA BEACH, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions,... Read more


Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients

TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patients TARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Naïve patients Favorable safety and tolerability profile observed with no Grade 3 or greater treatment-related adverse events reported Company obtained written feedback from FDA on registrational path forward for TARA-002 in BCG-Naïve patients Company... Read more


STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy

CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- STRM.BIO, a start-up biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced that it has been awarded a contract from the Advanced Research Projects Agency for Health (ARPA-H) through its Engineering of Immune Cells Inside the Body (EMBODY) program. EMBODY is led by ARPA-H Program Manager Daria Fedyukina, Ph.D. The award includes up to $8.4 million in funding to support... Read more


Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology

Safusidenib demonstrated durable responses, with an ORR of 44% and 88% of patients were progression-free at 24 months Findings supported recent favorable interactions with FDA where alignment was reached on modifying the ongoing G203 into a pivotal trial in high-grade gliomas NEW YORK / Dec 03, 2025 / Business Wire / Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the... Read more


Crinetics Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Initiation of trial marks milestone for Crinetics’ novel nonpeptide drug conjugate platform SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine tumors and other SST2-expressing solid tumors. CRN09682 is the lead candidate from... Read more


Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors

Initial clinical data expected mid-2026  SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the patients in the first cohort have been dosed in its Phase 1 trial evaluating STRO-004 in a range of Tissue Factor (TF) expressing solid tumors. STRO-004 is the Company’s... Read more


Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8 Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8’s potential disease modifying activity Company has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathway Clene is hosting an investor... Read more


Annovis Bio To Present at the 2025 Annual Meeting of the Parkinson Study Group

MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG), taking place December 4-6, 2025 in San Diego, California. The presentation builds on momentum... Read more


ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory...

ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 months of follow-up Combination continues to be generally well-tolerated with a manageable safety profile LOTIS-7 trial is on track for complete patient enrollment in 1H 2026; plan to share full data at a medical meeting and submit for publication by end of 2026 Company to host conference call today at 8:00 a.m.... Read more


Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Type C Meeting with U.S. Food and Drug Administration (FDA) Scheduled for Second Half of January  PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that its expanded access program has reached full enrollment. Each of the individuals enrolled in the program are being treated with 100 mg... Read more


Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustained release intravesical formulation of gemcitabine/docetaxel (Gem/Doce), into Phase 3 studies in two indications in H1 2026 Company is focused on high-risk NMIBC and intermediate-risk NMIBC, representing about 80% of new NMIBC cases every year, or about 54,000 people in... Read more


Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy

Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03 and p=0.04, respectively) Statistical significance was achieved in all type 1 error controlled secondary endpoints Results demonstrate clinically meaningful and statistically significant skeletal and cardiac benefits, supporting Deramiocel as a potential first-in-class... Read more


Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals observed to date PFS data for 1L NSCLC patients expected in Q2 2026; Company continues to explore partnership opportunities for pivotal development of silevertinib Based on encouraging CNS activity of silevertinib in multiple trials across NSCLC and GBM,... Read more


Microbix Biosystems & Seegene Mexico Collaborate to Improve Test Accuracy

Making HPV Tests & Quality Assessment Products Available across Mexico MISSISSAUGA, Ontario and MEXICO CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and Seegene Mexico S.A.P.I. de C.V. (Seegene Mexico), a firm focused upon transforming molecular diagnostics with innovative multiplex solutions, announce that Microbix external third-party quality assessment... Read more


NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation

As previously announced, low dose D-cycloserine has been associated with augmentation of the antidepressant and antisuicidal response achieved by Transcranial Magnetic Stimulation (TMS). NRx has amended its Investigational New Drug filing for NRX-101 (D-cycloserine/lurasidone) to include its use in association with TMS for the treatment of depression, including suicidal depression. This protocol will be available to patients both through a clinical trial and under NRx’s... Read more


Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001) All secondary efficacy endpoints met (p<0.0001), including End of Progression™1 (median 17.47 minutes) and complete symptom resolution (median 11.95 hours) Well-tolerated safety profile of deucrictibant confirmed Efficacy and safety outcomes consistent across all HAE subtypes represented (HAE type 1, HAE type 2, and HAE with... Read more


Immuron New U.S. Department of Defense Award & Clinical Trial Update

Highlights: New US Department of Defense award to develop two new oral therapeutics targeting Campylobacter and Shigella Uniformed Services University P2TD clinical study update MELBOURNE, Australia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, announces a new research agreement with the Naval Medical Research Command (NMRC) and the Walter Reed Army Institute of... Read more


Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date

STAFFORD, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date The Company has achieved a major milestone by screening over 1,000 patients in Flamingo-01,... Read more


BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno

SUNNYVALE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the election of Mr. Marvin Slosman to its Board of Directors, effective December 2, 2025. Dr. Richard Krasno, who has served on the Board since 2016, has completed his term and departed the Board effective December 2, 2025. “We are very pleased to... Read more


Alnylam Pharmaceuticals Announces Changes to Board of Directors

Mike Bonney and Carolyn Bertozzi to Depart; Company Appoints Stuart Arbuckle as New Independent Director  CAMBRIDGE, Mass. / Dec 03, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of two directors and the appointment of a new independent director. Mike Bonney and Carolyn Bertozzi, Ph.D., who have served in key roles on Alnylam’s... Read more


Clene to Provide CNM-Au8® ALS Program Update

Webcast set for 8:30 a.m. ET on December 3rd SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced it plans provide an update on its CNM-Au8... Read more


ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

Company to host corporate webcast to share updated data on December 3, 2025 LAUSANNE, Switzerland, Dec. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Wednesday, December 3, 2025, at 8:00 a.m. EST to provide an update on the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and... Read more


Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026...

Late-breaking HERIZON-GEA-01 presentation highlights the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancers Jazz to host investor webcast on Friday, January 9, 2026, to review data DUBLIN, Dec. 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced two abstracts featuring key data for Ziihera® (zanidatamab-hrii) have been accepted for presentation at the American Society of Clinical Oncology... Read more


FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit

SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11, 2025, in New York, NY. Thane Wettig, Chief Executive Officer of FibroGen, will participate in a panel titled Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts on Thursday, December 11 at 12:15... Read more


Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial of silevertinib and provide a program update on Wednesday, December 3, 2025, at 8:00am ET. Webcast information The... Read more


PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise

Toronto, Ontario--(Newsfile Corp. - December 2, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the therapeutic potential of ketamine for neuropsychiatric disorders, today announced it has closed the previously announced sale of its Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP to a leading sterile-injectables pharmaceutical company. At... Read more


Creative Medical Technology Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201

Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel’s advancement across large unmet-need global markets PHOENIX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company developing next-generation regenerative and immune cell therapies, today announced that the World... Read more


Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also to treat patients with non-ischemic dilated cardiomyopathy Non-ischemic dilated cardiomyopathy is a progressive disorder with no current cure, often leading to heart transplantation No approved treatments for aging-related frailty, a syndrome affecting older individuals... Read more


Hemostemix to Attend DFCon San Antonio and Closed its Private Placement

Calgary, Alberta--(Newsfile Corp. - December 2, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to announce its participation in DFCon 2025, hosted by the American Limb Preservation Society in San Antonio, Texas - the global epicentre for innovation in diabetic foot care, vascular medicine, and limb preservation. With more than 500 delegates expected, DFCon gathers the widest spectrum of professionals shaping the future of diabetic limb salvage: podiatrists,... Read more


IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

New Caregiver Resource Showcases Expert Contributions and Reinforces IGC Pharma's Leadership in Alzheimer's Innovation POTOMAC, MD / ACCESS Newswire / December 2, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced the publication of "Caring for a Loved One with Alzheimer's Disease: First Hand Ex... Read more


Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study

Jaguar's requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia® A novel non-antibiotic approach to diarrhea treatment is important because there are no FDA-approved drugs to treat general diarrhea in dogs, the second most common reason for visits to veterinary emergency hospitals SAN FRANCISCO, CA / ACCESS Newswire / December 2, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), today announced that its Italian... Read more


Alpha Tau Medical Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer

FDA approval marks Alpha Tau’s fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT’s reach into recurrent prostate cancer  JERUSALEM, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with... Read more


PDS Biotechnology Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval Pathway PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that its request for a Type C Meeting with the FDA has been accepted by the agency, and the... Read more


NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine

FDA has determined that NRx’s Abbreviated New Drug Application (ANDA) is “substantially complete” and received for review. Assigned GDUFA goal date is July 29, 2026. NRx has applied to FDA for use of KETAFREE™ as a proprietary product name, which is subject to review. KETAFREE™ is the first preservative-free ketamine formulation that does not include potentially toxic preservatives used in current multidose presentations of ketamine. Current worldwide generic... Read more


Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025

CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host an investor event on Sunday, December 7, 2025 at 7:00 a.m. ET to review new clinical data from the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD). These data will also be presented at the 67th American... Read more


Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

LANGHORNE, Pa. / Dec 02, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) has issued patent No. 4 496 611 titled, “Drug-Device Combination Comprising a Liquid Solution and a Nebulizer for Aerosolization of the Liquid Solution.” The patent is jointly held by Savara and PARI and covers the combination of Savara’s investigational therapy,... Read more